OBIO Financial Statements

Balance sheet, income statement, cash flow, and dividends for Orchestra Biomed Holdings Inc (OBIO).


$152.05M Market Cap.

As of 04/03/2025 5:00 PM ET (MRY) • Disclaimer

OBIO Market Cap. (MRY)


OBIO Shares Outstanding (MRY)


OBIO Assets (MRY)


Total Assets

$76.17M

Total Liabilities

$43.22M

Total Investments

$47.05M

OBIO Income (MRY)


Revenue

$2.64M

Net Income

-$61.02M

Operating Expense

$66.73M

OBIO Cash Flow (MRY)


CF Operations

-$50.56M

CF Investing

$13.09M

CF Financing

$29.17M

OBIO Dividends (MRY)


Period

Dividends

Yield %

Growth %

Payout Ratio

Coverage Ratio

2024

$0

0%

0%

0%

-

2023

$0

0%

0%

0%

-

2022

$0

0%

0%

0%

-

2021

$0

0%

0%

0%

-

2020

$0

0%

-

0%

-

OBIO Balance Sheet (MRY)


Metric

2024

2023

2022

2021

Total Assets

$76,173,000 (-20.00%)

$95,212,000 (-0.38%)

$95,572,000 (606.53%)

$13,527,000 (-64.49%)

Assets Current

$69,171,000 (-22.38%)

$89,114,000 (5.22%)

$84,690,000 (648.21%)

$11,319,000 (-68.78%)

Assets Non-Current

$7,002,000 (14.82%)

$6,098,000 (-43.96%)

$10,882,000 (392.84%)

$2,208,000 (20.13%)

Goodwill & Intangible Assets

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Shareholders Equity

$32,958,000 (-51.56%)

$68,043,000 (29.52%)

$52,534,000 (365.59%)

-$19,780,000 (59.25%)

Property Plant & Equipment Net

$3,487,000 (23.04%)

$2,834,000 (-22.91%)

$3,676,000 (228.21%)

$1,120,000 (9.06%)

Cash & Equivalents

$22,261,000 (-27.15%)

$30,559,000 (54.46%)

$19,784,000 (99.07%)

$9,938,000 (-51.15%)

Accumulated Other Comprehensive Income

$52,000 (620.00%)

-$10,000 (-25.00%)

-$8,000 (0%)

$0 (0%)

Deferred Revenue

$15,428,000 (-11.50%)

$17,433,000 (-10.78%)

$19,539,000 (-12.78%)

$22,401,000 (7.05%)

Total Investments

$47,046,000 (-20.97%)

$59,531,000 (-10.47%)

$66,496,000 (4803.83%)

$1,356,000 (-91.33%)

Investments Current

$44,551,000 (-21.89%)

$57,036,000 (-10.88%)

$64,001,000 (6580.69%)

$958,000 (-93.80%)

Investments Non-Current

$2,495,000 (0.00%)

$2,495,000 (0.00%)

$2,495,000 (526.88%)

$398,000 (115.14%)

Inventory

$173,000 (18.49%)

$146,000 (-47.10%)

$276,000 (305.88%)

$68,000 (-1.45%)

Trade & Non-Trade Receivables

$92,000 (-7.07%)

$99,000 (3.13%)

$96,000 (-20.66%)

$121,000 (-27.98%)

Trade & Non-Trade Payables

$5,134,000 (77.03%)

$2,900,000 (-26.92%)

$3,968,000 (95.56%)

$2,029,000 (14.37%)

Accumulated Retained Earnings (Deficit)

-$309,878,000 (-24.52%)

-$248,854,000 (-24.59%)

-$199,734,000 (-20.23%)

-$166,126,000 (-16.08%)

Tax Assets

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Tax Liabilities

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Total Debt

$16,529,000 (879.79%)

$1,687,000 (-85.79%)

$11,870,000 (109.24%)

$5,673,000 (-40.01%)

Debt Current

$550,000 (-15.25%)

$649,000 (-6.89%)

$697,000 (-65.15%)

$2,000,000 (-50.00%)

Debt Non-Current

$15,979,000 (1439.40%)

$1,038,000 (-90.71%)

$11,173,000 (204.19%)

$3,673,000 (-32.68%)

Total Liabilities

$43,215,000 (59.06%)

$27,169,000 (-36.87%)

$43,038,000 (29.22%)

$33,307,000 (-5.33%)

Liabilities Current

$16,207,000 (44.60%)

$11,208,000 (-39.63%)

$18,566,000 (51.68%)

$12,240,000 (-14.78%)

Liabilities Non-Current

$27,008,000 (69.21%)

$15,961,000 (-34.78%)

$24,472,000 (16.16%)

$21,067,000 (1.19%)

OBIO Income Statement (MRY)


Metric

2024

2023

2022

2021

Revenues

$2,638,000 (-4.42%)

$2,760,000 (-21.88%)

$3,533,000 (551.79%)

-$782,000 (-113.71%)

Cost of Revenue

$204,000 (9.68%)

$186,000 (-11.85%)

$211,000 (6.03%)

$199,000 (37.24%)

Selling General & Administrative Expense

$23,931,000 (18.13%)

$20,258,000 (44.35%)

$14,034,000 (77.02%)

$7,928,000 (-26.82%)

Research & Development Expense

$42,804,000 (26.56%)

$33,822,000 (54.12%)

$21,945,000 (70.25%)

$12,890,000 (-4.36%)

Operating Expenses

$66,735,000 (23.40%)

$54,080,000 (50.31%)

$35,979,000 (72.83%)

$20,818,000 (-14.36%)

Interest Expense

$0 (0%)

$0 (0%)

-$50,000 (-105.39%)

$927,000 (380.06%)

Income Tax Expense

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Loss Income from Discontinued Operations

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Consolidated Income

-$61,024,000 (-24.23%)

-$49,120,000 (-46.16%)

-$33,608,000 (-46.03%)

-$23,014,000 (-7.77%)

Net Income to Non-Controlling Interests

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Income

-$61,024,000 (-24.23%)

-$49,120,000 (-46.16%)

-$33,608,000 (-46.03%)

-$23,014,000 (-7.77%)

Preferred Dividends Income Statement Impact

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Income Common Stock

-$61,024,000 (-24.23%)

-$49,120,000 (-46.16%)

-$33,608,000 (-46.03%)

-$23,014,000 (-7.77%)

Weighted Average Shares

$36,821,042 (10.82%)

$33,225,227 (121.67%)

$14,988,584 (69.97%)

$8,818,115 (337.98%)

Weighted Average Shares Diluted

$36,821,042 (10.82%)

$33,225,227 (121.67%)

$14,988,584 (69.97%)

$8,818,115 (337.98%)

Earning Before Interest & Taxes (EBIT)

-$61,024,000 (-24.23%)

-$49,120,000 (-45.94%)

-$33,658,000 (-52.39%)

-$22,087,000 (-1.85%)

Gross Profit

$2,434,000 (-5.44%)

$2,574,000 (-22.52%)

$3,322,000 (438.63%)

-$981,000 (-117.65%)

Operating Income

-$64,301,000 (-24.84%)

-$51,506,000 (-57.72%)

-$32,657,000 (-49.81%)

-$21,799,000 (-16.25%)

OBIO Cash Flow Statement (MRY)


Metric

2024

2023

2022

2021

Net Cash Flow from Investing

$13,089,000 (22.48%)

$10,687,000 (116.67%)

-$64,122,000 (-592.60%)

$13,017,000 (-51.73%)

Net Cash Flow from Financing

$29,171,000 (-36.88%)

$46,215,000 (-55.24%)

$103,257,000 (2685.95%)

-$3,993,000 (-139.93%)

Net Cash Flow from Operations

-$50,558,000 (-9.61%)

-$46,127,000 (-57.49%)

-$29,289,000 (-50.75%)

-$19,429,000 (25.80%)

Net Cash Flow / Change in Cash & Cash Equivalents

-$8,298,000 (-177.01%)

$10,775,000 (9.44%)

$9,846,000 (194.63%)

-$10,405,000 (-196.49%)

Net Cash Flow - Business Acquisitions and Disposals

-$602,000 (0%)

$0 (0%)

$0 (0%)

-$213,000 (-15.14%)

Net Cash Flow - Investment Acquisitions and Disposals

$13,980,000 (29.87%)

$10,765,000 (116.94%)

-$63,531,000 (-570.46%)

$13,504,000 (-51.23%)

Capital Expenditure

-$289,000 (-270.51%)

-$78,000 (86.80%)

-$591,000 (-115.69%)

-$274,000 (49.17%)

Issuance (Repayment) of Debt Securities

$15,000,000 (238.26%)

-$10,849,000 (-405.26%)

$3,554,000 (188.85%)

-$4,000,000 (-140.00%)

Issuance (Purchase) of Equity Shares

$15,275,000 (5913.78%)

$254,000 (-99.77%)

$110,030,000 (1571757.14%)

$7,000 (0%)

Payment of Dividends & Other Cash Distributions

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Effect of Exchange Rate Changes on Cash

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Share Based Compensation

$10,615,000 (39.21%)

$7,625,000 (125.93%)

$3,375,000 (1017.55%)

$302,000 (36.65%)

Depreciation Amortization & Accretion

$962,000 (4.68%)

$919,000 (15.89%)

$793,000 (338.12%)

$181,000 (32.12%)

OBIO Financial Metrics (MRY)


Metric

2024

2023

2022

2021

Gross Margin

92.30% (-1.07%)

93.30% (-0.74%)

94.00% (-25.04%)

125.40% (28.62%)

Profit Margin

-2313.30% (-29.98%)

-1779.70% (-87.08%)

-951.30% (-132.32%)

2943.00% (885.85%)

EBITDA Margin

-2276.80% (-30.37%)

-1746.40% (-87.74%)

-930.20% (-133.21%)

2801.30% (841.28%)

Return on Average Equity (ROAE)

-135.20% (-131.90%)

-58.30% (-126.71%)

218.30% (-67.67%)

675.20%

Return on Average Assets (ROAA)

-79.60% (-91.81%)

-41.50% (-62.75%)

-25.50% (-38.59%)

-18.40%

Return on Sales (ROS)

-2313.30% (-29.98%)

-1779.70% (-86.81%)

-952.70% (-133.73%)

2824.40% (842.68%)

Return on Invested Capital (ROIC)

-138.90% (-160.60%)

-53.30% (-54.94%)

-34.40% (-85.95%)

-18.50%

Dividend Yield

0% (0%)

0% (0%)

0% (0%)

0% (0%)

Price to Earnings Ratio (P/E)

-2.41 (60.93%)

-6.17 (-38.47%)

-4.46 (-15.35%)

-3.86 (-219.97%)

Price to Sales Ratio (P/S)

55.83 (-49.20%)

109.91 (159.58%)

42.34 (137.25%)

-113.67 (-2613.62%)

Price to Book Ratio (P/B)

4.61 (-3.79%)

4.8 (-17.58%)

5.82 (155.84%)

-10.42 (-93.09%)

Debt to Equity Ratio (D/E)

1.31 (228.57%)

0.4 (-51.28%)

0.82 (148.63%)

-1.68 (-132.28%)

Earnings Per Share (EPS)

-1.66 (-12.16%)

-1.48 (33.93%)

-2.24 (14.18%)

-2.61 (75.40%)

Sales Per Share (SPS)

0.07 (-13.25%)

0.08 (-64.83%)

0.24 (365.17%)

-0.09 (-103.14%)

Free Cash Flow Per Share (FCFPS)

-1.38 (0.72%)

-1.39 (30.24%)

-1.99 (10.74%)

-2.23 (83.17%)

Book Value Per Share (BVPS)

0.9 (-56.30%)

2.05 (-41.57%)

3.5 (256.26%)

-2.24 (90.70%)

Tangible Assets Book Value Per Share (TABVPS)

2.07 (-27.81%)

2.87 (-55.05%)

6.38 (315.65%)

1.53 (-91.89%)

Enterprise Value Over EBIT (EV/EBIT)

-2 (66.67%)

-6 (14.29%)

-7 (22.22%)

-9 (25.00%)

Enterprise Value Over EBITDA (EV/EBITDA)

-2.14 (67.70%)

-6.61 (1.55%)

-6.72 (28.01%)

-9.33 (22.66%)

Asset Turnover

0.03 (47.83%)

0.02 (-14.81%)

0.03 (550.00%)

-0.01

Current Ratio

4.27 (-46.32%)

7.95 (74.29%)

4.56 (393.19%)

0.93 (-63.35%)

Dividends

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Free Cash Flow (FCF)

-$50,847,000 (-10.05%)

-$46,205,000 (-54.64%)

-$29,880,000 (-51.65%)

-$19,703,000 (26.27%)

Enterprise Value (EV)

$128,287,104 (-59.75%)

$318,727,464 (44.40%)

$220,718,520 (8.01%)

$204,352,705 (-21.38%)

Earnings Before Tax (EBT)

-$61,024,000 (-24.23%)

-$49,120,000 (-46.16%)

-$33,608,000 (-46.03%)

-$23,014,000 (-7.77%)

Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

-$60,062,000 (-24.61%)

-$48,201,000 (-46.66%)

-$32,865,000 (-50.03%)

-$21,906,000 (-1.66%)

Invested Capital

$54,234,000 (-1.63%)

$55,132,000 (-20.20%)

$69,092,000 (2420.08%)

-$2,978,000 (-123.19%)

Working Capital

$52,964,000 (-32.02%)

$77,906,000 (17.82%)

$66,124,000 (7279.59%)

-$921,000 (-104.21%)

Tangible Asset Value

$76,173,000 (-20.00%)

$95,212,000 (-0.38%)

$95,572,000 (606.53%)

$13,527,000 (-64.49%)

Market Capitalization

$152,054,104 (-53.41%)

$326,342,464 (6.75%)

$305,712,520 (48.31%)

$206,136,000 (-21.31%)

Average Equity

$45,122,500 (-46.42%)

$84,222,750 (646.95%)

-$15,398,548 (-351.77%)

-$3,408,485

Average Assets

$76,625,750 (-35.30%)

$118,433,250 (-10.11%)

$131,757,242 (5.50%)

$124,886,120

Invested Capital Average

$43,924,500 (-52.37%)

$92,221,000 (-5.73%)

$97,823,297 (-17.95%)

$119,222,060

Shares

38,013,526 (6.35%)

35,743,972 (16.69%)

30,632,517 (49.79%)

20,450,000 (0.00%)